An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term ...

(Corrects first bullet point showing median survival for trial patients as 21.1 months vs. 12.7 months, not 21.7 months vs 12 ...

The phase 3 VOLGA trial looks at perioperative durvalumab plus enfortumab vedotin, with and without tremelimumab, for muscle-invasive bladder cancer.

Scientists at the University of Pittsburgh uncovered the unstable immune cells that can cause up to 40% of immunotherapy ...

"The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC" takes up the trial that the panel calls the biggest ...

A short course of neoadjuvant immunotherapy continues to show long-term outcomes in patients with locally advanced mismatch ...

Late toxicities, immune deficiencies, infections, and secondary malignancies complicate cancer survivorship, making treatment ...

Researchers have discovered that immune cells normally responsible for controlling inflammation can develop inflammatory ...

Today, at the 2026 Boston Animal Health, Nutrition and Technology Innovation (AHNTI) Conference, VETARYS ( announced a ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 ...